Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b tulisokibart in moderate to severe hidradenitis suppurativa
jRCT2011250007Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of tulisokibart in hidradenitis suppurativa (HS) (4 arms), sponsored by Merck & Co. Primary endpoint: HiSCR50 at Week 16. Started Jul 2025; status: active, not recruiting.
02
Drugs
tulisokibart
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2011250007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250007.